CanSino Biologics Inc. (SHA:688185)
54.58
-0.26 (-0.47%)
Apr 25, 2025, 3:00 PM CST
CanSino Biologics Employees
CanSino Biologics had 1,494 employees as of December 31, 2023. The number of employees decreased by 797 or -34.79% compared to the previous year.
Employees
1,494
Change (1Y)
-797
Growth (1Y)
-34.79%
Revenue / Employee
566.49K CNY
Profits / Employee
-253.60K CNY
Market Cap
10.12B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Jiangsu Hengrui Medicine | 20,238 |
Shenzhen Mindray Bio-Medical Electronics | 18,044 |
WuXi AppTec | 39,414 |
Zhangzhou Pientzehuang Pharmaceutical., | 2,789 |
Aier Eye Hospital Group | 36,718 |
Sichuan Biokin Pharmaceutical | 2,086 |
Shanghai United Imaging Healthcare | 7,440 |
Yunnan Baiyao Group Co.,Ltd | 9,277 |
CanSino Biologics News
- 2 years ago - Riding Covid Vaccine Highs, CanSino Plans Swiss Listing - Seeking Alpha
- 2 years ago - World-First Inhaled COVID-19 Vaccine, Developed in Partnership Between Aerogen® and CanSinoBIO, First Public Booster Immunization in China. - Business Wire
- 2 years ago - China's CanSinoBIO H1 revenue drops on weaker COVID shot demand - Reuters
- 3 years ago - CanSinoBIO's COVID-19 Vaccine Convidecia™ Receives WHO Emergency Use Listing - PRNewsWire
- 3 years ago - CanSinoBIO Rebrands to Reflect Commitment to Life Sciences Research - PRNewsWire
- 3 years ago - CanSinoBIO's COVID-19 mRNA Vaccine Receives Approval of Clinical Trial Application in China - PRNewsWire
- 3 years ago - CanSinoBIO's Convidecia™ Approved as Heterologous Booster in Malaysia and Indonesia - PRNewsWire
- 3 years ago - Latest Study Shows Advantages of CanSinoBIO's Convidecia™ as Heterologous Booster against Omicron Variant - PRNewsWire